Form 4: uniQure Director Leonard Post Granted Equity Awards Under Incentive Plan

uniQure N.V. Director Leonard E. Post was granted 7,970 restricted share units and 15,630 stock options on June 11, 2025, as part of the company's 2014 Share Incentive Plan.

Summary

• Leonard E. Post, a Director of uniQure N.V. (QURE), received equity awards on June 11, 2025.
• The awards consist of 7,970 Restricted Share Units (RSUs) and 15,630 Stock Options.
• The RSUs were granted at a price of $0 and represent the contingent right to receive one Ordinary Share each.
• The Stock Options have an exercise price of $16.22 per share and were also granted at a price of $0.
• Both the RSUs and Stock Options are scheduled to vest 100% on the first anniversary of the grant date, which is June 11, 2026, provided Mr. Post maintains his relationship with uniQure.
• Following these transactions, Mr. Post directly beneficially owns 32,049 Ordinary Shares and 15,630 Stock Options.
• The Stock Options are set to expire on June 11, 2035.
• These grants were made under the Issuer's 2014 Share Incentive Plan, as amended and restated.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is generally a positive sign of alignment and retention, though it introduces minor future dilution. It's a standard compensation event.

Positives

• The grant of equity awards to Director Leonard E. Post aligns his interests with those of shareholders, incentivizing long-term performance and retention.
• The awards are part of a structured and pre-existing incentive plan (2014 Share Incentive Plan), indicating a standard approach to executive compensation.

Negatives

• The future vesting and exercise of these equity awards will result in a minor dilution of existing shareholders' ownership.

Risks

• Potential future dilution for existing shareholders upon the vesting and exercise of the granted restricted share units and stock options.
• The value realized from the stock options is contingent on uniQure N.V.'s stock price exceeding the exercise price of $16.22 in the future.

Future Outlook

The document indicates future vesting of equity awards on June 11, 2026, contingent on the director's continued relationship with the company, aligning future compensation with company performance.

Industry Context

Equity grants to directors and executives are a common practice in the biotechnology and pharmaceutical industries, including gene therapy companies like uniQure, to attract, retain, and incentivize key talent. These compensation structures are designed to align management's interests with long-term shareholder value creation, a critical aspect in R&D-intensive sectors with long development cycles.

Comparison to Industry Standards

• The grant of restricted share units and stock options to a director is a standard compensation practice within the biotechnology and pharmaceutical sectors.
• While specific comparable companies or projects are not detailed in this filing, such equity-based incentives are widely used by peers to align executive and director interests with shareholder value.
• Similar equity compensation plans are prevalent at companies like Sarepta Therapeutics, Bluebird Bio, and CRISPR Therapeutics, which also operate in the gene therapy space, though the specific size and terms of grants vary based on company size, performance, and individual roles.

Related Party Transactions

• The grant of 7,970 Restricted Share Units and 15,630 Stock Options to Leonard E. Post, a Director of uniQure N.V., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Minor potential future dilution from the vesting and exercise of equity awards, but also potential benefit from improved director alignment and retention.
• Employees: No direct impact mentioned for general employees, but the existence of a share incentive plan suggests similar mechanisms may be available to other key personnel.

Next Steps

• The Restricted Share Units and Stock Options are scheduled to vest on June 11, 2026.
• The Stock Options will expire on June 11, 2035.

Key Dates

Recommendation

Keywords

uniQure N.V., QURE, SEC Form 4, Insider Transaction, Equity Grant, Restricted Share Units, RSUs, Stock Options, Director Compensation, Share Incentive Plan, Beneficial Ownership